'Combination chemotherapy' presentation slideshows

Chemotherapy for Metastatic Colon Cancer

Scott Berry Sunnybrook Health Sciences Centre. Chemotherapy for Metastatic Colon Cancer. Where Were We Until 2000?. O. F. HN. O. N H. 5-FU. oxaliplatin. irinotecan. C. H. 3. C. H. O. 2. O. N. N. N. O. C. O. O. N. H. O. C. H. C. H. 2. 3. NH 2. O. C. Pt. O.

1.47k views • 83 slides

Multisystem Diseases

Multisystem Diseases. Sharon H. de Kock September 2012. LYMPHOID NEOPLASM.

781 views • 56 slides

Bladder Cancer

Bladder Cancer. 2nd Clinic of Urology Medical University of Lodz. Adam Madej M.D. Marek Lipi?ski M.D. Ph.D. Associated Professor of Urology. EBM. Guidelineses.

1.3k views • 56 slides

Clinical Applications of Therapeutic Apheresis

Clinical Applications of Therapeutic Apheresis. Diseases Treated with TA. Guillain-Barre Syndrome 11% Myasthenia Gravis 12% CIDP 8%. Cryoglobulinemia 30% Anti-GBM Disease 30% Pauci-immune RPGN 13% SLE nephropathy 10% Myeloma kidney 7% Recurrent FSG 5% Renal transplantation 5%.

723 views • 45 slides

Nutritional Support Antineoplastic Therapy

Nutritional Support Antineoplastic Therapy. Principles of IV Therapy BSN336. Nutritional Support. The care of individuals with potential or known nutritional alterations. Nutritional Support. Goals of Parenteral nutrition include:

767 views • 39 slides

Age Specific Incidence Rates of Pancreas Cancer, in California, by Race, 1988-2008

Saint Agnes Medical Center Oncology Symposium October 15, 2011 Neoadjuvant, Adjuvant and Palliative Management Marshall Flam, MD Hematology, Oncology Medical Group. Age Specific Incidence Rates of Pancreas Cancer, in California, by Race, 1988-2008. Courtesy of Paul Mills, PhD, MPH.

534 views • 36 slides

Professor Elhamy Rifky 2010

469 views • 34 slides

Common Adjuvant Regimens

417 views • 25 slides

GYNAECOLOGY RADIOTHERAPY AND CHEMOTHERAPY IN GYNAECOLOGY ?. ????? ???????

GYNAECOLOGY RADIOTHERAPY AND CHEMOTHERAPY IN GYNAECOLOGY ?. ????? ???????. PRINCIPLES OF RADIATION THERAPY

777 views • 19 slides

Reviewer: Dr Scott Berry Date posted: June 21, 2007

CAPEOX vs. FOLFOX4 +/- Bevacizumab: survival results from NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC) Authors: Cassidy, Saltz et al. Reviewer: Dr Scott Berry Date posted: June 21, 2007. Background.

270 views • 12 slides

Hodgkin Disease

Hodgkin Disease. Definition: neoplastic disorder with development of specific infiltrate containing pathologic Reed-Sternberg cells. It usually arises in lymph nodes and spreads to contiguous groups. Extranodal presentation are rare. Disease is associated with defective cellular immunity.

1.56k views • 11 slides

Study Design

Sequential first line treatment for metastatic colorectal cancer with capecitabine, irinotecan and bevacizumab: capecitabine plus bevacizumab (Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-Bev): The AIO KRK 0110 / ML22011 randomized, phase III trial.

167 views • 1 slides